Axicabtagene Ciloleucel (Axi-cel) has transitioned from a third-line ‘hail mary’ therapy to a definitive second-line standard of care for high-risk Large B-cell Lymphoma (LBCL).
The ZUMA-7 trial demonstrated a significant improvement in event-free survival (EFS) compared to the long-standing standard of platinum-based salvage and autologous stem cell transplant (ASCT).
Long-term follow-up from the ZUMA-1 trial confirms the potential for functional cure, with a five-year overall survival rate exceeding 40% in previously refractory patients.
Expanding indications now include relapsed/refractory Mantle Cell Lymphoma (ZUMA-2) and Indolent Follicular Lymphoma (ZUMA-5).
